Sandra Silberman

CNS Research (United States) — United States

Medicine · Health Sciences

18h-index13.5kcitations66works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(20), Glioma Diagnosis and Treatment(15), Chronic Myeloid Leukemia Treatments(14), Acute Myeloid Leukemia Research(12), Gastrointestinal Tumor Research and Treatment(11)

Publications66 total

EXTH-133. Activity of Berubicin, a novel anthracycline, in Pediatric Diffuse Midline Glioma (DMG) cells: Preliminary data and future possibilities
Neuro-Oncology·2025Open Access
CTNI-70. TPI 287, WHICH IN COMBINATION WITH BEVACIZUMAB (BEV) HAS SHOWN ACTIVITY IN PATIENTS WITH GLIOBLASTOMA (GBM) AFTER PRIOR THERAPY, TO BE EVALUATED IN A PHASE 2 TRIAL AS WELL AS IN OTHER CNS DISEASES
Neuro-Oncology·2025Open Access
CTNI-74. PRIMARY RESULTS OF THE RANDOMIZED CLINICAL TRIAL OF BERUBICIN VS LOMUSTINE IN PATIENTS WITH GLIOBLASTOMA AFTER FAILURE OF PRIMARY THERAPY: DATA ANALYSIS AND FUTURE POSSIBILITIES
Neuro-Oncology·2025Open Access
CTNI-68. UPDATES ON A POTENTIALLY PIVOTAL TRIAL CNS-201: A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN VS. LOMUSTINE AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM)
Neuro-Oncology·2024· 1 citedOpen Access
RMTD-03 USE OF A BRAIN-PENETRATING ANTHRACYCLINE IN ANTHRACYCLINE-SENSITIVE BRAIN METASTASES: THE PROMISE OF BERUBICIN
Neuro-Oncology Advances·2024· 1 citedOpen Access
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma
Neuro-Oncology Advances·2024· 3 citedOpen Access
CTNI-35. A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN VS. LOMUSTINE AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): INTERIM RESULTS OF A PRE-PLANNED ANALYSIS OF OVERALL SURVIVAL (OS)
Neuro-Oncology·2023Open Access
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Journal of Clinical Oncology·2023· 141 cited
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
Annals of Hematology·2023· 9 citedOpen Access
TIPS-20 A RANDOMIZED, CONTROLLED TRIAL OF BERUBICIN, A TOPOISOMERASE II POISON THAT APPEARS TO CROSS THE BLOOD-BRAIN BARRIER (BBB), AFTER FIRST-LINE THERAPY FOR GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS
Neuro-Oncology Advances·2023Open Access
Supplementary Tables 1 - 3 from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
2023Open Access
Supplementary Figures 1 & 2 from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
2023Open Access
Supplementary Figures 1 & 2 from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
2023Open Access
Data from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
2023Open Access
Data from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
2023Open Access
Supplementary Tables 1 - 3 from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
2023Open Access
Supplementary Data from A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023Open Access
Supplementary Table S7 from A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023Open Access
Supplementary Table S7 from A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023Open Access
Data from A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Samuel Singer(10), Saša Dimitrijević(10), Amer M. Zeidan(9), Maya Ridinger(9), Tara L. Lin(9), Pamela S. Becker(9), Gary J. Schiller(8), Prapti A. Patel(8), Mark G. Erlander(8), Sigmund Hsu(8), Alexander I. Spira(7), Eunice S. Wang(7), Samuel Goldlust(7), Burt Nabors(7), Tara Benkers(6), George Farmer(6), George D. Demetri(5), Peter Roberts‎(5), Renaud Capdeville(5), Christopher D.�M. Fletcher(5)